Trials / Unknown
UnknownNCT04893252
Vactosertib and Durvalumab in Gastric Cancer
Vactosertib in Combination With Durvalumab (MEDI4736) in Patients With Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- Hark Kyun Kim · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will test the efficacy and safety of durvalumab in combination with vactosertib in patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy
Detailed description
Efficacy and safety of durvalumab (anti-PD-L1) via IV infusion Q4W, in combination with vactosertib (TGF-beta inhibitor) PO bid for 5 days a week for up to a maximum of 12 months, will be tested in patients with metastatic hypermutated gastric cancers as ≥ 3rd-line setting until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | durvalumab and vactosertib | durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week) |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2021-05-19
- Last updated
- 2022-11-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04893252. Inclusion in this directory is not an endorsement.